Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (4381)	7/31/2001 12:25:27 PM
From: Biomaven	Respond to of 52153

<<JNJ's extended release ritalin>> Agreed this is a serious competitor. This drug (Concerta - originally marketed by AZA) now has a 20% market share amongst the analeptics, up from about 12% at the beginning of the year. Adderal (the non-ritalin competitor) has been steady at about 1/3 of the market. The time-release stuff for ritalin is weird - you actually need pulses to get an effect rather than the standard steady blood level that you usually want in a time release. I assume Novartis has the time-release version of the CELG drug under serious development. Peter